Ischemic risk after PCI is assessed using clinical, procedural, and angiographic factors. Several scoring systems and risk models help guide DAPT duration and intensity based on ischemic vs. bleeding risk.
Ischemic risk after PCI is assessed using clinical, procedural, and angiographic factors. Several scoring systems and risk models help guide DAPT duration and intensity based on ischemic vs. bleeding risk.
Key Factors for Ischemic Risk Assessment:
1. Patient-related factors:
• History of myocardial infarction (MI)
• Diabetes mellitus
• Chronic kidney disease (CKD)
• Peripheral artery disease (PAD)
• Heart failure or reduced LVEF (<40%)
2. Procedural factors:
• Complex PCI (e.g., multiple stents, bifurcation, long lesions)
• Left main or proximal LAD disease
• Multi-vessel disease
3. Angiographic factors:
• Residual coronary disease with high plaque burden
• Suboptimal stent deployment (high restenosis risk)
Scoring Systems for Ischemic Risk:
• DAPT Score (≥2 suggests benefit from prolonged DAPT)
• PARIS Score (predicts ischemic vs. bleeding risk post-PCI)
• GRACE Score (for ACS patients to estimate recurrent MI risk)
Clinical decision-making: Patients with high ischemic risk and low bleeding risk may benefit from longer DAPT (≥12 months), while those at high bleeding risk should receive shorter DAPT (1–6 months) followed by monotherapy.
The DAPT (Dual Antiplatelet Therapy) Score is a clinical tool used to assess the ischemic and bleeding risk for patients undergoing PCI (Percutaneous Coronary Intervention). The score helps determine the optimal duration of dual antiplatelet therapy (DAPT) after stent implantation.
DAPT Score Components:
1. Age:
• < 60 years: +2 points
• 60-74 years: +1 point
• ≥ 75 years: 0 points
2. Myocardial Infarction (MI) at presentation:
• Yes: +2 points
• No: 0 points
3. Stent type:
• Drug-eluting stent (DES): +1 point
• Bare-metal stent (BMS): 0 points
4. Diabetes mellitus:
• Yes: +1 point
• No: 0 points
5. Current smoker:
• Yes: +1 point
• No: 0 points
6. Peripheral artery disease (PAD):
• Yes: +1 point
• No: 0 points
7. History of stroke/TIA:
• Yes: 0 points
• No: +1 point
Interpretation of DAPT Score:
• DAPT Score ≥ 2: High ischemic risk, suggesting longer duration of DAPT (12 months or more).
• DAPT Score ≤ 1: Lower ischemic risk, suggesting shorter duration of DAPT.
This scoring system helps clinicians balance the ischemic and bleeding risks and guide the duration of DAPT after PCI.
Bleeding risk assessment is critical in determining the optimal duration of dual antiplatelet therapy (DAPT) after PCI. Several tools and scores are used to evaluate bleeding risk in patients on DAPT, the most commonly used being the HAS-BLED score.
HAS-BLED Score:
The HAS-BLED score is designed to assess the 1-year risk of major bleeding in patients with atrial fibrillation, but it is also useful for patients receiving antiplatelet therapy, including those undergoing PCI.
Components of the HAS-BLED Score:
1. Hypertension:
• Uncontrolled hypertension (systolic BP >160 mmHg): +1 point
2. Abnormal renal function (dialysis, transplant, or creatinine >2.26 mg/dL):
• Yes: +1 point
3. Abnormal liver function (chronic liver disease or bilirubin >2x upper limit of normal or AST/ALT >3x normal):
• Yes: +1 point
4. Stroke history:
• Yes: +1 point
5. Bleeding history or predisposition (e.g., GI bleeding, anemia):
• Yes: +1 point
6. Labile INRs (for patients on warfarin or other anticoagulants):
• Yes: +1 point
7. Age ≥ 65 years:
• Yes: +1 point
8. Drugs (antiplatelet agents, NSAIDs, or anticoagulants):
• Yes: +1 point
9. Alcohol consumption (≥8 drinks/week):
• Yes: +1 point
Interpretation of HAS-BLED Score:
• Score 0-2: Low bleeding risk, meaning DAPT duration can be safely longer.
• Score 3 or more: High bleeding risk, and a shorter DAPT duration or careful management is recommended.
This helps clinicians weigh the potential for bleeding versus the benefit of reducing ischemic events when determining the duration of DAPT post-PCI.
